JNJ-56021927
Showing 1 - 25 of 445
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Castration-Resistant Prostate Cancer Trial in Worldwide (Apalutamide)
Active, not recruiting
- Castration-Resistant Prostate Cancer
-
Greenville, South Carolina
- +4 more
Aug 2, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Apalutamide, Biopsy, Biospecimen Collection)
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Apalutamide
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2023
Prostate Adenocarcinoma Trial in Seattle (Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment)
Terminated
- Prostate Adenocarcinoma
- Apalutamide
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 28, 2021
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone Trial in Houston (Abiraterone
Active, not recruiting
- Metastatic Prostate Carcinoma
- +5 more
- Abiraterone Acetate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 26, 2022
Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 Trial in United States (Apalutamide,
Recruiting
- Localized Prostate Carcinoma
- +8 more
- Apalutamide
- Quality-of-Life Assessment
-
Tucson, Arizona
- +4 more
Jun 28, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate
Suspended
- Castration-Resistant Prostate Carcinoma
- +4 more
- Abiraterone Acetate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 27, 2022
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 Trial in Houston (drug,
Completed
- Prostate Adenocarcinoma
- +4 more
- Abiraterone Acetate
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 Trial in Houston (drug, procedure,
Recruiting
- Prostate Carcinoma
- +6 more
- Abiraterone Acetate
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Aug 10, 2022
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 Trial in Los Angeles (drug,
Not yet recruiting
- Prostate Adenocarcinoma
- +3 more
- Apalutamide
- +7 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 5, 2023
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7 Trial in
Completed
- Stage III Prostate Adenocarcinoma AJCC v7
- +3 more
- Abiraterone Acetate
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 15, 2021
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Houston,
Active, not recruiting
- Castration Levels of Testosterone
- +4 more
- Abiraterone Acetate
- +6 more
-
Houston, Texas
- +2 more
Feb 11, 2022
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression Trial in San Francisco (Apalutamide,
Recruiting
- Castration Levels of Testosterone
- +3 more
- Apalutamide
- Stereotactic Body Radiation Therapy
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 26, 2021
Prostate Cancer Trial in La Jolla, Boston, New York (Apalutamide, Leuprolide, Prednisone)
Prostatic Tumors, Castration-Resistant Trial in Japan (JNJ-56021927)
Completed
- Prostatic Neoplasms, Castration-Resistant
- JNJ-56021927
-
Fukuoka, Japan
- +3 more
Apr 24, 2020
Prostatic Tumors Trial in Worldwide (Apalutamide, Abiraterone acetate, Prednisone)
Active, not recruiting
- Prostatic Neoplasms
- Apalutamide
- +3 more
-
Phoenix, Arizona
- +183 more
Jan 17, 2023
Prostatic Tumors Trial in Brazil, Colombia, Mexico (Apalutamide, ADT (Standard of Care))
Available
- Prostatic Neoplasms
- Apalutamide
- ADT (Standard of Care)
-
Florianopolis, Brazil
- +19 more
Aug 2, 2022
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma Trial in Houston
Withdrawn
- Biochemically Recurrent Prostate Carcinoma
- +5 more
- Apalutamide
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 14, 2021
Prostate Cancer Trial in Worldwide (Apalutamide, Placebo, Androgen Deprivation Therapy (ADT))
Castration-Resistant Prostatic Tumors Trial in Worldwide (Cetrelimab 480 mg, Apalutamide 240 mg)
Completed
- Castration-Resistant Prostatic Neoplasms
- Cetrelimab 480 mg
- Apalutamide 240 mg
-
San Francisco, California
- +33 more
Feb 24, 2022